Navigation Links
Myriad Genetics Presents Tumor Origin Technology at AACR

Determining Tumor Origin May Be Useful in Cancer Treatment Decisions

SALT LAKE CITY, UT, April 18, 2007--Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it presented studies for a new technology that might be used to determine the original location of a metastatic tumor, on Monday, April 16, 2007 at the annual meeting of the American Association for Cancer Research (AACR) in Los Angeles, California. This work could also prove helpful in determining whether any two tumors are related, and was carried out in collaboration with researchers from Magee-Womens Hospital and the University of Pittsburgh Medical Center.

Tumor origin can play an important role in choosing among treatment options for cancer patients. A difficult problem in treating some gynecological malignancies is determining the primary site of tumor origin. This is particularly apparent when cancer simultaneously involves both the ovary and endometrium. Myriad has developed a technology based on DNA copy number analysis, which may be used to accurately distinguish between the different possible originating or primary tumors.

The preliminary data from Myriad's study came from patient specimens with diagnoses of simultaneous ovarian and endometrial cancers. Three separate specimens were collected and analyzed for DNA copy number from each patient, one from the ovarian tumor, one from the endometrial tumor and one from normal unaffected tissue.

In many cases, pathologists may be unable to distinguish between related tumors and separate primary tumors due to the uncertain nature of the pathology results. The copy number analysis either confirmed conclusions from pathological examination, or provided new information that could be used to give a more positive determination of tumor source. Copy number analysis can show that both tumors share a change
'"/>




Page: 1 2 3

Related medicine technology :

1. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Myriad Genetics Presents Tumor Origin Technology AACR
(Date:6/2/2015)... June 2, 2015  Only a quarter of physicians ... the patients they prescribe them to, according to new ... of Medicine (BUSM) and myCME , Haymarket ... Daniel Alford, M.D. , director of BUSM,s Safe ... , said, "This indicates a critical need for provider ...
(Date:6/2/2015)... , June 2, 2015  ErgoNurse, the leader in ... of healthcare products in the United States ... nursing home, long-term care and skilled nursing markets. ... ... able to fully take advantage of the ErgoNurse products to ...
(Date:6/2/2015)...  CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached an agreement to settle the ... Court of Chancery, which names as defendants ... and officers, and names the Company as a nominal ... CytRx Corp. Stockholder Derivative Litigation , C.A. No. 9864-VCL, ...
Breaking Medicine Technology:Survey Results Show Few Doctors Are Very Confident Managing Patients on Opioids 2ErgoNurse and Briggs Healthcare Positioned to Completely Eliminate the Unnecessary Cost of Healthcare-Related Back Injuries 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4
(Date:6/2/2015)... Though almost the entire Park family was born ... rule their lives. Organizing and hosting the June 14 event ... to the fullest and spreading awareness of HHT. , “I've ... won't live my life in a bubble because something bad ... is to look back on your life with regret because ...
(Date:6/2/2015)... 02, 2015 Vancouver, BC – ... Research ( http://www.idataresearch.com ), the bone graft substitute ... matrices (DBM) over traditional allograft materials. Because the ... thus an increase in operation time, alternative graft ... growth in these synthetic materials is partly the ...
(Date:6/2/2015)... Recent findings from the 2014 National Youth ... a reduction in conventional cigarette smoking, use of electronic ... has doubled among today’s teens in a year. ... national trend is consistent with what is occurring locally, ... to fully determine the long-term effects of e-cigarette usage ...
(Date:6/2/2015)... PhishLine, LLC today announced it ... Drive, Suite 125 in Waukesha, Wisconsin 53186. ... base of operations for PhishLine’s current corporate staff ... , Mark Chapman, Founder and President, commented “PhishLine ... enterprise customers adopt our market leading service to ...
(Date:6/2/2015)... 2015 Mercy Health (formerly Catholic Health ... Kentucky – has devoted the seventh of its monthly ... cancer prevention. One in five Americans will get skin ... YouTube channel, a Mercy Health expert addresses these skin ... causes of skin cancer? ,     What are the ...
Breaking Medicine News(10 mins):Health News:Family brings awareness to genetic disease at first Memphis walk 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 3Health News:Susquehanna Health Pediatrician Warns of Adverse Effects of Teen E-Cigarette Usage 2Health News:Susquehanna Health Pediatrician Warns of Adverse Effects of Teen E-Cigarette Usage 3Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Video provides helpful information about skin cancer prevention 2
... constipation are more likely to get diagnosed with the progressive ... have// some effect on the function of the gut long ... led the research, said: "It could help us more effectively ... high risk of developing the disease in the future." The ...
... type of childhood brain cancer has a unique molecule ... fight it.// Armed with targeted molecular treatments, doctors may ... side effects of prolonged and powerful radiation and chemotherapy ... a collaborative effort looking at a type of childhood ...
... A new invenvtion in the medical history. A team of ... a 68-year old woman using a remote controlled robot. This ... medical history. The operation took place at the European Institute ... it is a phenomenal step and we cannot even begin ...
... the Institute of Health Sciences in Oxford found that women ... to have a stillbirth, or to develop pre-eclampsia.// Taking low-dose ... researchers. ,The researchers reviewed more than 23 previous ... of anti-platelet drugs, of which low-dose aspirin is the most ...
... errors in the alpha gene are the cause of premature ... affects about 2% of the total population.// ,The University ... development of a genetic test, which would allow women with ... are at risk. They analysed DNA from women who had ...
... and marketing rights of the anti-anthrax vaccine developed by the ... is expected that the vaccine would be in the market ... to JNU for the exclusive rights. In addition, it will ... is yet to make any projections on the business the ...
Cached Medicine News:
... is a solid solution for ... package includes the Vibratome Plus, ... blocks, v-block adapter, specimen mounts ... stage assembly for ease in ...
... Vibratome Semi-Automatic Tissue Sectioning System has maintained ... sectioning system. Researchers from around the globe ... for their fresh and fresh fixed tissue ... With the Vibratome Automatic Tissue Sectioning ...
... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
... NEW Vibratome 3000 Plus Sectioning System provides ... fixed, animal, or plant tissues. The ... allows sectioning without freezing or embedding. ... morphology, the destruction of enzyme activities, and ...
Medicine Products: